CLYBL and Lennox-Gastaut syndrome: Phase III placebo-controlled RCT in LGS (12-week maintenance period) (44):Significantly greater reduction in total seizures for CLB vs. PBO: average weekly rates decreased 9.3% for PBO vs. 34.8% (p = 0.0414), 45.3% (p = 0.0044) and 65.3% (p < 0.0001) for CLB 0.25, 0.5, and 1 mg/kg/day, respectively